[go: up one dir, main page]

AU6910994A - Methods and compounds for inhibiting cell proliferative disorders characterized by abnormal (abl) activity - Google Patents

Methods and compounds for inhibiting cell proliferative disorders characterized by abnormal (abl) activity

Info

Publication number
AU6910994A
AU6910994A AU69109/94A AU6910994A AU6910994A AU 6910994 A AU6910994 A AU 6910994A AU 69109/94 A AU69109/94 A AU 69109/94A AU 6910994 A AU6910994 A AU 6910994A AU 6910994 A AU6910994 A AU 6910994A
Authority
AU
Australia
Prior art keywords
abl
abnormal
activity
compounds
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU69109/94A
Inventor
Yinon Ben-Neriah
Aviv Gazit
Chaim Gilon
Alexander Levitzki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yissum Research Development Co of Hebrew University of Jerusalem
Original Assignee
Yissum Research Development Co of Hebrew University of Jerusalem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL105707A external-priority patent/IL105707A0/en
Application filed by Yissum Research Development Co of Hebrew University of Jerusalem filed Critical Yissum Research Development Co of Hebrew University of Jerusalem
Publication of AU6910994A publication Critical patent/AU6910994A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU69109/94A 1993-05-14 1994-05-13 Methods and compounds for inhibiting cell proliferative disorders characterized by abnormal (abl) activity Abandoned AU6910994A (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US236420 1988-08-25
IL105707A IL105707A0 (en) 1993-05-14 1993-05-14 Tyrphostins and compositions containing them
IL105707 1993-05-14
US23432794A 1994-04-27 1994-04-27
US234327 1994-04-27
US23642094A 1994-04-28 1994-04-28
PCT/US1994/005294 WO1994026260A1 (en) 1993-05-14 1994-05-13 METHODS AND COMPOUNDS FOR INHIBITING CELL PROLIFERATIVE DISORDERS CHARACTERIZED BY ABNORMAL abl ACTIVITY

Publications (1)

Publication Number Publication Date
AU6910994A true AU6910994A (en) 1994-12-12

Family

ID=27271604

Family Applications (1)

Application Number Title Priority Date Filing Date
AU69109/94A Abandoned AU6910994A (en) 1993-05-14 1994-05-13 Methods and compounds for inhibiting cell proliferative disorders characterized by abnormal (abl) activity

Country Status (2)

Country Link
AU (1) AU6910994A (en)
WO (1) WO1994026260A1 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981569A (en) * 1992-11-13 1999-11-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Substituted phenylacrylonitrile compounds and compositions thereof for the treatment of disease
US5763441A (en) * 1992-11-13 1998-06-09 Sugen, Inc. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
IL107736A (en) * 1993-11-24 2001-01-11 Yissum Res Dev Co Pharmaceutical composition for the prevention of septic shock and for the treatment of chronic inflammatory diseases
US5700823A (en) * 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
WO1995024190A2 (en) * 1994-03-07 1995-09-14 Sugen, Inc. Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
CA2187752A1 (en) * 1994-04-22 1995-11-02 Chaim M. Roifman Use of benzylidene-malononitrile derivates for the treatment of leukemia
US5721277A (en) * 1995-04-21 1998-02-24 Sugen, Inc. Compounds and methods for inhibiting hyper-proliferative cell growth
US6331555B1 (en) 1995-06-01 2001-12-18 University Of California Treatment of platelet derived growth factor related disorders such as cancers
WO1996040629A1 (en) * 1995-06-07 1996-12-19 Sugen, Inc. Tyrphostin-like compounds for the treatment of cell proliferative disorders or cell differentiation disorders
US6316479B1 (en) 1997-05-19 2001-11-13 Sugen, Inc. Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders
EP1060160A2 (en) * 1998-02-27 2000-12-20 THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Disubstituted lavendustin a analogs and pharmaceutical compositions comprising the analogs
CA2265396A1 (en) * 1999-03-12 2000-09-12 Chaim M. Roifman Methods and compositions for treating leukemia
US20020002169A1 (en) 1999-12-08 2002-01-03 Griffin John H. Protein kinase inhibitors
DE10123587B4 (en) * 2001-05-08 2005-04-07 Schering Ag Cyanoanthranylamide derivatives and their use as pharmaceuticals
ATE323694T1 (en) 2001-05-08 2006-05-15 Schering Ag CYANOANTHRANYLAMIDE DERIVATIVES AND THEIR USE AS MEDICINAL PRODUCTS
DE10123573B4 (en) * 2001-05-08 2005-06-02 Schering Ag N-Oxidanthranylamide derivatives and their use as pharmaceuticals
US7307071B2 (en) * 2001-12-04 2007-12-11 Onyx Pharmaceuticals, Inc RAF-MEK-ERK pathway inhibitors to treat cancer
US7615565B2 (en) 2002-07-31 2009-11-10 Bayer Schering Pharma Aktiengesellschaft VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines
US7511066B2 (en) 2003-09-30 2009-03-31 Eli Lilly And Company Antithrombotic aromatic ethers
US7906533B2 (en) 2004-11-03 2011-03-15 Bayer Schering Pharma Ag Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
EP1657241A1 (en) 2004-11-03 2006-05-17 Schering Aktiengesellschaft Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors
EP1655295A1 (en) 2004-11-03 2006-05-10 Schering Aktiengesellschaft Anthranilamide pyridinureas as VEGF receptor kinase inhibitors
US8703808B2 (en) 2009-06-23 2014-04-22 Centre National De La Recherche Scientifique Use of derivatives of indoles for the treatment of cancer
EP2266562A1 (en) * 2009-06-23 2010-12-29 Centre National de la Recherche Scientifique Use of derivatives of indoles for the treatment of cancer
WO2015042053A1 (en) * 2013-09-17 2015-03-26 Pharmakea, Inc. Vinyl autotaxin inhibitor compounds

Also Published As

Publication number Publication date
WO1994026260A1 (en) 1994-11-24

Similar Documents

Publication Publication Date Title
AU6910994A (en) Methods and compounds for inhibiting cell proliferative disorders characterized by abnormal (abl) activity
AU4091497A (en) Method for detecting kinase activity
IL112921A0 (en) Methods and compositions for inhibiting cell proliferative disorders
AU6112896A (en) Tyrphostin-like compounds for the treatment of cell prolifer ative disorders or cell differentiation disorders
AU4615693A (en) Method for access control
AU4754393A (en) Cell culture insert
AU4572893A (en) Method for seed encrusting
AU4754493A (en) Cell culture insert
AU5068393A (en) Link piece for bony elements
AU3738289A (en) Distribution system for downflow reactors
AU7330094A (en) Device for containing secondary smoke
AU7729694A (en) Method for inhibiting metalloproteinase expression
ZA969177B (en) 4-Phenyl-4-oxo-2-butanoic acid derivatives with kynurenine-3-hydroxylase inhibiting activity
GB9522617D0 (en) 4-Phenyl-4-oxo-butenoic acid derivatives with kynurenine-3-hydroxylase inhibiting activity
EP1144997A3 (en) Methods and compounds for modulating nuclear receptor activity
AU7749394A (en) Methods for inhibiting uterine fibrosis
AU1846297A (en) Method for inhibiting tumor cell growth
AU6803694A (en) Cell growth regulators
EP0516549A3 (en) Method for regulating enzyme activities by noble gases
AU3835697A (en) Method for inhibiting the growth of mammalian cells
AU3554793A (en) Improved amorphous adsorbent-based refining methods
AU2283497A (en) Methods for increasing the maturation of cells
AU4463093A (en) Process for continuous electrochemical lead refining
AU6413594A (en) Substituted 3-phenanthridinone derivatives as 5alpha-reductase inhibitors
ZA943305B (en) Methods and compounds for inhibiting cell proliferative disorders characterized by abnormal activity